Current Drug Combination News and Events

Current Drug Combination News and Events, Drug Combination News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 25 | 1000 Results
New therapeutic approach may help treat age-related macular degeneration effectively
Runt-related transcription factor 1 (RUNX1) has been linked to retinal neovascularization and the development of abnormal blood vessels, which result in vision loss in diabetic retinopathy. Now, scientists have found that RUNX1 inhibition presents a new therapeutic approach in the treatment of age-related macular degeneration (AMD), which is the leading cause of blindness in the elderly worldwide. Their results are reported in The American Journal of Pathology, published by Elsevier. (2021-02-22)

Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit. (2021-02-18)

UCLA study finds combination therapy suppresses pancreatic tumor growth in mice
UCLA Jonsson Comprehensive Cancer Center researchers have uncovered a potential new way to target pancreatic tumors that express high intratumoral interferon signaling (IFN). (2021-02-18)

Chatter between cell populations drives progression of gastrointestinal tumors
Researchers at University of California San Diego School of Medicine identified new therapeutic targets for gastrointestinal stromal tumors (GISTs) that could lead to new treatment options for patients. (2021-02-18)

Vets' depression, social support & psychological resilience play role in later well being
Veterans who experienced the combination of low depression, high social support and high psychological resilience as they left military service were most likely to report high well-being a year later. (2021-02-17)

Combination treatment for common glioma type shows promise in mice
Gliomas are common brain tumors that comprise about one third of all cancers of the nervous system. In a study funded by the National Institutes of Health (NIH), researchers tested a novel combination treatment approach on mice with tumors with characteristics similar to human astrocytomas and found tumor regression in 60 percent of the mice treated. These encouraging results could be the first step toward developing a treatment for this type of brain cancer. (2021-02-16)

Immunotherapy -- targeted drug combination improves survival in advanced kidney cancer
Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial. (2021-02-13)

Researchers identify potential revolutionary new drug treatment for fatal childhood cancer
Research paper published reveals potential revolutionary drug combination that could become an effective treatment for DIPG. (2021-02-12)

Brain tumor study reveals surprising gene deletion and method to overcome drug resistance
Experts at Cincinnati Children's report success at averting drug resistance in a subtype of brain tumors called glioblastomas. Importantly, the research indicates that the approach may also work in other cancers, such as melanoma, that exhibit a similar pathway of drug resistance. (2021-02-10)

Radiation vulnerability
Exposure to radiation can wreak indiscriminate havoc on cells, tissues, and organs. Curiously, however, some tissues are more vulnerable to radiation damage than others. A new study now finds that cellular survival after radiation exposure depends on behavior of the tumor-suppressor protein p53 over time. In vulnerable tissues, p53 levels go up and remain high, leading to cell death. In tissues that tend to survive radiation damage, p53 levels oscillate up and down. (2021-02-09)

Combination therapy with radiation shows promise in treating glioblastoma
In a study of mice, researchers at the UCLA Jonsson Comprehensive Cancer Center have identified a new approach that combines an anti-psychotic drug, a statin used to lower high cholesterol levels, and radiation to improve the overall survival in mice with glioblastoma (2021-02-09)

Type 2 diabetes: drugs initially increase glucose production
Although SGLT-2 inhibitors are central to the treatment of diabetes, their exact mode of action was hitherto unknown. A study shows that there is a direct correlation between the elimination of glucose via the kidneys and new glucose production in the liver. (2021-02-08)

New drug target for Ebola, Marburg viruses
Researchers have identified a previously unknown site on the filovirus glycoprotein to which small drug molecules can bind and prevent infection -- blocking both sites may be a more effective treatment while reducing the risk of side effects. (2021-02-08)

New combination therapy offers chance of healing hepatitis B
Around 260 million people, more than three percent of the global population, are chronically infected with the hepatitis B virus (HBV); in the long term, this often leads to complications such as liver cirrhosis and liver cancer. A cure is not yet possible with the available medication. Scientists at the German Center for Infection Research (DZIF) and the University Hospital Eppendorf (UKE) have now investigated a new combination therapy that has proven highly effective in their infection model. (2021-02-04)

Popular breast cancer drugs don't work the way we thought they did
New research suggests that a class of drugs called PARP inhibitors, designed to treat hereditary forms of ovarian and breast cancer, don't work the way we thought they did. It also paints a fuller picture of how they work, opening the door to improvements in next-generation drugs. (2021-02-03)

Gene mutations linked to worse outcomes from leukemia in Hispanic and Latino children
A combination of genetic mutations may explain the higher incidence of and poorer outcomes from pediatric leukemia in Hispanic and Latino children, according to Penn State College of Medicine researchers. They said a novel therapeutic drug combination - as well as testing for these mutations - may help address the disparity. (2021-02-02)

BU researchers identify promising therapeutic agent against melanoma
There have been great advances in treating melanoma over the past five years, however, even with these treatments many patients quickly develop drug resistance and die from their disease. A new study from Boston University School of Medicine (BUSM) has discovered that a drug (YK-4-279) that was previously created to target one specific type of protein has much broader use against a family of proteins that act to promote melanoma. (2021-02-01)

Risk-taking linked to particular brain features
There is a common genetic and neurobiological basis for risky behavior - the genetic disposition for risk-taking is mapped in several areas of the brain, a UZH study shows. The study combines genetic information and brain scans from more than 25,000 people for the first time. (2021-01-28)

Nanoparticle drug delivery technique shows promise for treating pancreatic cancer
Veterans Affairs researchers have designed a new way to deliver pancreatic cancer drugs that could make fighting the disease much easier. (2021-01-28)

Gut microbiota reveals whether drug therapies work in inflammatory bowel diseases
A study recently completed at the University of Helsinki indicates that the gut microbiota of patients suffering from inflammatory gastrointestinal disorders can be used to predict whether they will benefit from expensive therapies. The study also confirms the key role of therapies that have a beneficial effect on the gut microbiota in inflammatory bowel diseases. (2021-01-26)

Nixing bone cancer fuel supply offers new treatment approach, mouse study suggests
An innovative approach to treating bone tumors - starving cancer cells of the energy they need to grow - could one day provide an alternative to a commonly used chemotherapy drug without the risk of severe side effects, suggests a new study from Washington University School of Medicine in St. Louis. (2021-01-26)

Potential combined drug therapy for lung cancer
Researchers at Kanazawa University report in Clinical Cancer Research that in the most common type of lung cancer, certain secondary mutations occurring with another gene alteration known as ALK make the efficacy of alectinib, an otherwise commonly used drug for treating lung cancer, become unfavorable. Combining alectinib with another kind of drug can overcome this adverse effect, however. (2021-01-22)

University of Cincinnati research unveils possible new combo therapy for head and neck cancer
Researchers at the University of Cincinnati have tested a new combination therapy in animal models to see if they could find a way to make an already effective treatment even better. Since they're using a Food and Drug Administration-approved drug to do it, this could help people sooner than later. (2021-01-22)

Pre-surgery chemotherapy is possible for early stage pancreatic cancer patients
A first-of-its-kind randomized clinical trial found that patients with pancreatic cancer didn't live any longer than expected after receiving pre-operative chemotherapy from either of the two standard regimens, according to trial results published in JAMA Oncology. (2021-01-21)

Researchers uncover potentially promising therapeutic combination for renal cell carcinoma
Investigators have demonstrated that ACE2 expression is a good prognostic factor in RCC, that loss of ACE2 mediates resistance to classical treatments, and that in preclinical models, treatment with a drug that is downstream of ACE2 can improve tumor responses in RCC and significantly prolong survival. (2021-01-20)

New method heals skeletal injuries with synthetic bone
Researchers at Lund University in Sweden, in collaboration with colleagues in Dresden, Germany, have developed a way of combining a bone substitute and drugs to regenerate bone and heal severe fractures in the thigh or shin bone. The study, published in the research journal Science Advances, was conducted on rats, but the researchers think that the method in various combinations will soon be commonplace in clinical settings. (2021-01-19)

New combination drug therapy offers hope against methamphetamine addiction
A new treatment that combines two existing medications may provide long-sought relief for many battling debilitating methamphetamine use disorder, according to a study to be published tomorrow in The New England Journal of Medicine. (2021-01-14)

UNH researchers discover new inhibitor drug combination for rare form of cancer
Researchers at the University of New Hampshire took the novel approach of targeting specific cell proteins that control DNA information using inhibitors, or drugs, that were effective in reducing the growth of the Waldenström macroglobulinemia cancer cells and when combined with a third drug were even more successful in killing the WM cancer cells which could lead to more treatment options. (2021-01-14)

New England Journal of Medicine publishes COVID-19 treatment trial results
In a multicenter study funded by the National Institutes of Health, a combination of two drugs, baricitinib and remdesivir, reduced time to recovery in hospitalized COVID-19 patients. The results from sites including UT Health San Antonio and University Health were published Dec. 11 in the New England Journal of Medicine. (2021-01-14)

Nanotechnology prevents premature birth in mouse studies
In a study in mice and human cells, Johns Hopkins Medicine researchers say that they have developed a tiny, yet effective method for preventing premature birth. (2021-01-13)

Drug combination increases susceptibility to chemotherapy in cases of severe neuroblastoma
Researchers at the University of Gothenburg now suggest a possible cure for children with hard-to-treat forms of neuroblastoma using a new combination of drugs. In a new study in the journal Cancer Research, they describe how a two small molecule-based drug combination likely inhibit the tumor's growth. (2021-01-07)

A prognostic Alzheimer's disease blood test in the symptom-free stage
Using a blood test, a German-Dutch research team has predicted the risk of Alzheimer's disease in people who were clinically diagnosed as not having Alzheimer's disease but who perceived themselves as cognitively impaired (Subjective Cognitive Declined, SCD). The researchers analyzed blood samples from an SCD cohort supervised at the Alzheimer Center Amsterdam. Using a test developed in Bochum, they identified all 22 subjects at study entry who developed Alzheimer's dementia, thus the clinical symptoms, within six years. (2021-01-06)

Ibrutinib with rituximab in previously untreated CLL: indication of added benefit over FCR
Ibrutinib with rituximab in previously untreated CLL: indication of added benefit over FCR. The new drug combination prolongs overall survival in patients in good general health. No study data are available for other patient groups. (2021-01-05)

Heat treatment may make chemotherapy more effective
The study, published in the Journal of Materials Chemistry B, found that ''loading'' a chemotherapy drug on to tiny magnetic particles that can heat up the cancer cells at the same time as delivering the drug to them was up to 34% more effective at destroying the cancer cells than the chemotherapy drug without added heat. (2021-01-05)

UC researcher urges caution using remdesivir to treat COVID-19
Research at the University of Cincinnati, however, contends that this antiviral drug is being used too indiscriminately when treating patients hospitalized with the virus. The study is published in the journal Fundamental & Clinical Pharmacology. (2020-12-29)

Ludwig Cancer Research study reveals how ecDNA forms and drives cancer drug resistance
Researchers led by Ludwig San Diego Member Don Cleveland and Peter Campbell of the Sanger Center have solved the mystery of how free-floating circular DNA fragments, which are almost exclusively found in cancer cells, drive gene amplification to generate drug resistance in cancer. (2020-12-23)

Triple chemotherapy combination improves metastatic colorectal cancer outcomes
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination -- of irinotecan, cetuximab, and vemurafenib -- is a more powerful tumor fighter and keeps people with metastatic colon cancer disease free for a significantly longer period of time compared with patients treated with irinotecan and cetuximab. (2020-12-23)

New drug combination could improve glucose and weight control in diabetes
Scientists have shown that adding an experimental cancer drug to a widely used diabetes treatment improves blood glucose control and weight loss in mice, according to a study published today in eLife. (2020-12-22)

Safe gun storage counseling and lock distribution could lower military suicide rate
Military members who receive gun locks and lethal means counseling, which focuses on ways to limit a person's access to specific methods for suicide, are more likely to use a gun safe and unload firearms before they are stored, according to the Gun Violence Research Center, based at Rutgers (2020-12-22)

Lithuanian researchers propose combination of methods to improve anticancer drug delivery
Application of low-intensity pulsed ultrasound in combination with microbubbles might enhance the delivery of chemotherapy medication used for treating cancers. In their study, a team of Lithuanian researchers from three universities - KTU, LSMU and VMU - claim that the rate of microbubble survival time is the best indicator for determining the efficiency of sonoporation, i.e. ultrasound-induced laceration of the cancer cell membrane. (2020-12-17)

Page 1 of 25 | 1000 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.